



## **Antengene's ATG-022 Clinical Study Achieves Positive Results: CR Achieved in Elderly Gastric Cancer Patient**

Recent reports from official channels indicate that in Antengene's Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate), **an elderly patient with advanced gastric cancer who has progressed on multiple lines of chemotherapy, immunotherapy and targeted therapy despite extensive metastases achieved a complete response (CR) following ATG-022 monotherapy. The patient's tumor-free status was confirmed by PET/CT in May 2025.**

**ATG-022 is a CLDN18.2 ADC discovered and developed in-house by Antengene.** At the ASCO GI 2025 conference earlier this year, Antengene presented updated clinical data for ATG-022. In patients with moderate-to-high CLDN18.2 expression (IHC 2+  $\geq$  20%), the objective response rate (ORR) was 42.9%, and the disease control rate (DCR) was 95.2%. Among patients with low CLDN18.2 expression (IHC 2+ < 20%), the ORR was 30.0%, and the DCR was 50.0%. These data demonstrate that ATG-022 delivers clinically meaningful efficacy and favorable safety profile across a spectrum of CLDN18.2 expression levels, including high, low, and even ultra-low expression. Its broad-spectrum antitumor activity suggests that ATG-022 may offer therapeutic benefits to a wider patient population compared to other CLDN18.2-targeted therapies. **Currently, the Phase II dose-expansion study of ATG-022 is ongoing in the mainland of China and Australia.**

This achievement of a CR in this elderly gastric cancer patient is extremely encouraging, highlighting the therapeutic potential of ATG-022 as a novel ADC therapy. **Importantly, this is not the only CR observed in the ongoing study. To date, three CR cases have been observed, including patients from both**



**the mainland of China and Australia. Antengene looks forward to presenting updated data from the ATG-022 study at the upcoming ESMO Congress in October 2025.** The company remains fully committed to advancing the CLINCH study and accelerating the development of ATG-022 as a potential first-in-class and best-in-class therapeutic option for patients with CLDN18.2-positive cancers. This progress reflects Antengene's unwavering commitment to its vision: "Treating Patients Beyond Borders." With responsibility as our foundation and innovation as our guide, we continue to pursue meaningful breakthroughs that bring a brighter outlook to cancer patients worldwide.

### **Forward-looking statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.